Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan
© 2023. Indian Society of Gastroenterology..
BACKGROUND/PURPOSE OF THIS STUDY: It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients' clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD.
METHODS: A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022.
RESULTS: Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn's disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p < 0.05). Female sex, younger age and current or former smoking were associated with an increased incidence of fever or chills after the initial dose of the vaccine (p < 0.05). In contrast, corticosteroid use was identified as a factor associated with an increased incidence of muscle pain after the initial dose of vaccine (p < 0.05).
CONCLUSION: The use of corticosteroids could increase the risk of muscle pain following COVID-19 vaccination. Additionally, factors such as female sex, younger age and current or former smoking can affect the incidence of fever or chills. This information should encourage patients with IBD to get vaccinated against COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology - 42(2023), 5 vom: 28. Okt., Seite 701-707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miyazaki, Haruka [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.09.2023 Date Revised 03.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12664-023-01386-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360052924 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360052924 | ||
| 003 | DE-627 | ||
| 005 | 20231226082206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12664-023-01386-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360052924 | ||
| 035 | |a (NLM)37505394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miyazaki, Haruka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Indian Society of Gastroenterology. | ||
| 520 | |a BACKGROUND/PURPOSE OF THIS STUDY: It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients' clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD | ||
| 520 | |a METHODS: A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022 | ||
| 520 | |a RESULTS: Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn's disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p < 0.05). Female sex, younger age and current or former smoking were associated with an increased incidence of fever or chills after the initial dose of the vaccine (p < 0.05). In contrast, corticosteroid use was identified as a factor associated with an increased incidence of muscle pain after the initial dose of vaccine (p < 0.05) | ||
| 520 | |a CONCLUSION: The use of corticosteroids could increase the risk of muscle pain following COVID-19 vaccination. Additionally, factors such as female sex, younger age and current or former smoking can affect the incidence of fever or chills. This information should encourage patients with IBD to get vaccinated against COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adrenal cortex hormones | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Drug-related side effects and adverse reactions | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a Myalgia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Surveys and questionnaires | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a Vaccines | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Watanabe, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Sayaka |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Norihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokunaga, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Yuna |e verfasserin |4 aut | |
| 700 | 1 | |a Ooi, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshi, Namiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kodama, Yuzo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology |d 1993 |g 42(2023), 5 vom: 28. Okt., Seite 701-707 |w (DE-627)NLM012713031 |x 0975-0711 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:5 |g day:28 |g month:10 |g pages:701-707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12664-023-01386-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 5 |b 28 |c 10 |h 701-707 | ||